# Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication

> **NCT02184767** · PHASE1 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 30 (actual)

## Conditions studied

- BiPolar

## Interventions

- **DRUG:** ADASUVE®

## Key facts

- **NCT ID:** NCT02184767
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2015-03
- **Final completion:** 2015-05
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02184767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02184767, "Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02184767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*